跳轉至內容
Merck
  • Inhibiting β-catenin disables nucleolar functions in triple-negative breast cancer.

Inhibiting β-catenin disables nucleolar functions in triple-negative breast cancer.

Cell death & disease (2021-03-06)
Shannon E Weeks, Sarah C Kammerud, Brandon J Metge, Heba A AlSheikh, David A Schneider, Dongquan Chen, Shi Wei, James A Mobley, Akinyemi I Ojesina, Lalita A Shevde, Rajeev S Samant
摘要

Triple-negative breast cancer (TNBC) patients with upregulated Wnt/β-catenin signaling often have poor clinical prognoses. During pathological examinations of breast cancer sections stained for β-catenin, we made the serendipitous observation that relative to non-TNBC, specimens from TNBC patients have a greater abundance of nucleoli. There was a remarkable direct relationship between nuclear β-catenin and greater numbers of nucleoli in TNBC tissues. These surprising observations spurred our investigations to decipher the differential functional relevance of the nucleolus in TNBC versus non-TNBC cells. Comparative nucleolar proteomics revealed that the majority of the nucleolar proteins in TNBC cells were potential targets of β-catenin signaling. Next, we undertook an analysis of the nucleolar proteome in TNBC cells in response to β-catenin inhibition. This effort revealed that a vital component of pre-rRNA processing, LAS1 like ribosome biogenesis factor (LAS1L) was significantly decreased in the nucleoli of β-catenin inhibited TNBC cells. Here we demonstrate that LAS1L protein expression is significantly elevated in TNBC patients, and it functionally is important for mammary tumor growth in xenograft models and enables invasive attributes. Our observations highlight a novel function for β-catenin in orchestrating nucleolar activity in TNBCs.

材料
產品編號
品牌
產品描述

Sigma-Aldrich
抗-β-肌动蛋白−过氧化物酶抗体,小鼠单克隆 小鼠抗, clone AC-15, purified from hybridoma cell culture